⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 2, 2021BMJOpen Access

Covid-19: Where are we on vaccines and variants?

Elisabeth Mahase

View Full Paper

Ask AI

Bookmark

Share

Abstract

Nearly a year after WHO declared the covid-19 pandemic, Elisabeth Mahase reports on the latest developments in vaccines, variants, and diplomacy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Elisabeth Mahase (2021) studied this question.

synapsesocial.com/papers/6a6fe0155d37378ac1dcec92 https://doi.org/10.1136/bmj.n597

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing intervalOriginal Research · 2021 · 48 citations
2Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissionsOriginal Research · 2021 · 20 citations
3Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variantHuman Clinical Trial · 2021 · 235 citations
4Covid-19: What have we learnt about the new variant in the UK?Original Research · 2020 · 109 citations
5Conflict and climate are compounding challenges for women’s and children’s healthBMJ · Wed,

More from BMJ

Acetic acid chromoendoscopy for detection of neoplastic Barrett’s oesophagus: stepped wedge cluster randomised controlled trial (ACID-trial)Wed,
Green transition provides a crucial opportunity to finance universal health coverageWed,
In South Asia the most vulnerable people are paying for a climate crisis created by high income countriesWed,
Effectiveness of a structured template to improve completeness of reporting randomised trial protocols: randomised controlled trialTue,
Wildfires are putting firefighters at risk of cancer—scientists are working out how to helpTue,